RGLS - Regulus Therapeutics Inc Stock Price, Fair Value and News

$8.16

Market Closed

RGLS Stock Valuation Analysis

Valuation

Max Portfolio %

RGLS Price Action

RGLS RSI Chart

RGLS Stock Valuation Analysis

Valuation

Max Portfolio %

RGLS Valuation

RGLS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RGLS Fundamentals

RGLS Revenue

RGLS Earnings

RGLS Profitability

RGLS Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.7M	2.5M	3.2M	3.8M
2023	976.0K	1.4M	1.7M	1.7M
2022	0	0	1.1M	562.0K
2021	0	10.4M	10.8M	5.9M
2020	7.6M	8.4M	9.2M	10.0M
2019	2.8M	4.1M	5.5M	6.8M
2018	72.0K	72.0K	72.0K	1.4M
2017	913.5K	633.0K	352.5K	72.0K
2016	15.9M	11.0M	6.1M	1.2M
2015	10.2M	13.3M	14.1M	20.8M
2014	18.0M	13.9M	8.9M	7.7M
2013	12.6M	14.0M	17.4M	19.6M
2012	13.8M	13.8M	12.8M	12.7M
2011	9.9M	11.2M	12.5M	13.8M
2010	0	0	0	8.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

CEO	Mr. Joseph P. Hagan M.B.A.
WEBSITE	regulusrx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	30